# US 2023/0405144 A1 · Inducible cell death systems

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0405144 A1
- Document ID: US20230405144A1
- Status: Published application
- Kind: A1
- Application number: 18/199,154
- Filed: 2023-05-18
- Published: 2023-12-21
- Earliest claimed: 2020-11-20
- Assignees: Senti Biosciences, Inc.
- Applicants: Senti Biosciences, Inc.
- Inventors: Rocky CHEUNG; Russell Morrison GORDLEY; Timothy Kuan-Ta LU; Michelle Elizabeth HUNG; Rebecca Tayler COTTMAN
- Web page: https://patentgrep.com/patent/US20230405144A1

## CPC

- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- C07K 14/4747: {Apoptosis related proteins}
- A61K 35/17: Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes (when activated by a specific antigen A61K39/00)
- A61K 47/64: Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent (peptidic linkers A61K47/65)
- A61K 47/6425: {the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell}
- A61K 47/67: {Enzyme prodrug therapy, e.g. gene directed enzyme drug therapy [GDEPT] or VDEPT}
- A61K 47/6813: {the drug being a peptidic cytokine, e.g. an interleukin or interferon}
- A61K 47/6815: {Enzymes}
- A61K 47/6829: {Bacterial toxins, e.g. diphteria toxins or Pseudomonas exotoxin A}
- A61K 47/6897: {Pre-targeting systems with two or three steps using antibody conjugates; Ligand-antiligand therapies}
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- C07K 14/721: {Steroid/thyroid hormone superfamily, e.g. GR, EcR, androgen receptor, oestrogen receptor}
- C07K 16/44: against material not provided for elsewhere {, e.g. haptens, metals, DNA, RNA, amino acids}
- A61P 35/00: Antineoplastic agents
- C07K 2317/569: Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C07K 2319/20: containing a tag with affinity for a non-protein ligand
- C07K 2319/70: containing domain for protein-protein interaction
- C07K 2319/81: containing a Zn-finger domain for DNA binding
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Provided herein are compositions and methods for inducing cell death in a regulated manner, for example in a safety switch system. Inducible cell death can be triggered by ligand binding to a one or more ligand binding domains. Cell death can include induction of apoptosis.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

A method of treating a subject in need thereof, comprising:
delivering to the subject in need thereof a therapeutically effective amount of an engineered cell comprising an inducible cell death system or an engineered nucleic acid comprising the inducible cell death system,
wherein the inducible cell death system comprises two or more polypeptide monomers, wherein each polypeptide monomer comprises one or more ligand binding domains and a cell death-inducing domain, wherein the polypeptide monomers are configured to oligomerize upon contacting the polypeptide monomers with a cognate ligand of the one or more ligand binding domains and generate a cell-death inducing signal in a cell in which the polypeptide monomers are expressed, and wherein:
i. each polypeptide monomer of the two or more polypeptide monomers comprises the same ligand binding domain, wherein the same ligand binding domain comprises a domain or functional fragment thereof selected from the group consisting of: a hormone-binding domain of estrogen receptor (ER) domain, optionally comprising the amino acid sequence of SEQ ID NO: 42; an ABI domain, optionally comprising the amino sequence of SEQ ID NO: 31; a PYL domain, optionally comprising the amino acid sequence of SEQ ID NO: 53; a caffeine-binding single-domain antibody, optionally comprising the amino acid sequence of SEQ ID NO: 33; a cannabidiol binding domain, optionally comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 34, 35, 36, 37, and 38; a heavy chain variable region (VH) of an anti-nicotine antibody, optionally comprising the amino acid sequence of SEQ ID NO: 50, and/or the light chain variable region (VL) of an anti-nicotine antibody, optionally comprising the amino acid sequence of SEQ ID NO: 51; optionally comprising the amino acid sequence of SEQ ID NO: 43; a progesterone receptor domain, optionally comprising the amino acid sequence of SEQ ID NO: 52; and combinations thereof; or
ii. a first polypeptide monomer of the two or more polypeptide monomers comprises a first ligand binding domain, a second polypeptide monomer of the two or more polypeptide monomers comprises a second ligand binding domain, and wherein the second ligand binding domain is different from the first ligand binding domain.

### Claim 22 (depends on 21)

The method of claim 21, wherein:
the first ligand binding domain of (ii) comprises a cereblon domain, optionally comprising the amino acid sequence set forth in one of SEQ ID NOs: 127 and 129, and wherein the second ligand binding domain of (ii) comprises a degron, optionally comprising the amino acid sequence set forth in one of SEQ ID NOs: 131 and 133, optionally wherein the cognate ligand is an IMiD, optionally wherein the IMiD is an FDA-approved drug, and optionally wherein the IMiD is selected from the group consisting of: thalidomide, lenalidomide, and pomalidomide; or
the first polypeptide monomer comprises a hormone-binding domain of estrogen receptor (ER) domain and the second polypeptide monomer comprises an FKBP domain, optionally wherein the cognate ligand is rapamycin or a derivative thereof and/or tamoxifen or a metabolite thereof; or
the first polypeptide monomer comprises an FRB domain and the second polypeptide monomer comprises a hormone-binding domain of estrogen receptor (ER) domain, optionally wherein the cognate ligand is rapamycin or a derivative thereof and/or tamoxifen or a metabolite thereof; or
wherein the first polypeptide monomer comprises a hormone-binding domain of estrogen receptor (ER) domain and an FKBP domain, and the second polypeptide monomer comprises an FRB domain and a hormone-binding domain of estrogen receptor (ER) domain, optionally wherein the cognate ligand is rapamycin or a derivative thereof and/or tamoxifen or a metabolite thereof; or
the first polypeptide monomer comprises an ABI domain and the second polypeptide monomer comprises a PYL domain, optionally wherein the cognate ligand comprises abscisic acid; or
the first polypeptide monomer comprises a heavy chain variable region (VH) of an anti-nicotine antibody and the second polypeptide monomer comprises a light chain variable region (VL) of an anti-nicotine antibody, optionally wherein the anti-nicotine antibody is a Nic12 antibody, optionally wherein the VH comprises the amino acid sequence of SEQ ID NO: 50, and optionally wherein the VL comprises the amino acid sequence of SEQ ID NO: 51, and optionally wherein the cognate ligand is nicotine or a derivative thereof; or
the first polypeptide monomer comprises a cannabidiol binding domain comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 35, 36, 37, and 38 and the second polypeptide monomer comprises a cannabidiol binding domain comprising the amino acid sequence of SEQ ID NO: 34. optionally wherein the cognate ligand is a phytocannabinoid, optionally wherein the phytocannabinoid is cannabidiol.

### Claim 23 (depends on 21)

The method of claim 21, wherein the cell death-inducing domain is derived from a protein selected from the group consisting of: caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, Diphtheria toxin fragment A (DTA), Bax, Bak, Bok, Bad, Bcl-xS, Bak, Bik, Bcl-2-interacting protein 3 (BNIP3), Fas, Fas-associated protein with death domain (FADD), tumor necrosis factor receptor type 1-associated death domain protein (TRADD), a TNF receptor (TNF-R), APAF-1, granzyme B, second mitochondria-derived activator of caspases (SMAC), Omi, Bmf, Bid, Bim, p53-upregulated modulator of apoptosis (PUMA), Noxa, Blk, Hrk, Cytochrome c, Arts, TNF-related cell death-inducing ligand (TRAIL), Herpes Simplex Virus thymidine kinase (HSV-TK), Varicella Zoster Virus thymidine kinase (VZV-TK), viral Spike protein, Carboxyl esterase, cytosine deaminase, nitroreductase Fksb, Carboxypeptidase G2, Carboxypeptidase A, Horseradish peroxidase, Linamarase, Hepatic cytochrome P450-2B1, and Purine nucleoside phosphorylase, optionally wherein the caspase 9 or a functional truncation thereof, comprises the amino acid sequence of SEQ ID NO: 39, optionally wherein the DTA comprises the amino acid sequence of SEQ ID NO: 41, optionally wherein the granzyme B comprises the amino acid sequence of SEQ ID NO: 47, optionally wherein the Bax comprises the amino acid sequence of SEQ ID NO: 32.

### Claim 24

A pharmaceutical composition comprising:
a) an inducible cell death system, an engineered nucleic acid encoding the inducible cell death system, or an engineered cell comprising the inducible cell death system, wherein the inducible cell death system comprises two or more polypeptide monomers, wherein each polypeptide monomer comprises one or more ligand binding domains and a cell death-inducing domain, wherein the polypeptide monomers are configured to oligomerize upon contacting the polypeptide monomers with a cognate ligand of the one or more ligand binding domains and generate a cell-death inducing signal in a cell in which the polypeptide monomers are expressed, and wherein:
i) each polypeptide monomer of the two or more polypeptide monomers comprises the same ligand binding domain, wherein the same ligand binding domain comprises a domain or functional fragment thereof selected from the group consisting of: a hormone-binding domain of estrogen receptor (ER) domain, optionally comprising the amino acid sequence of SEQ ID NO: 42; an ABI domain, optionally comprising the amino sequence of SEQ ID NO: 31; a PYL domain, optionally comprising the amino acid sequence of SEQ ID NO: 53; a caffeine-binding single-domain antibody, optionally comprising the amino acid sequence of SEQ ID NO: 33; a cannabidiol binding domain, optionally comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 34, 35, 36, 37, and 38; a heavy chain variable region (VH) of an anti-nicotine antibody, optionally comprising the amino acid sequence of SEQ ID NO: 50, and/or the light chain variable region (VL) of an anti-nicotine antibody, optionally comprising the amino acid sequence of SEQ ID NO: 51; optionally comprising the amino acid sequence of SEQ ID NO: 43; a progesterone receptor domain, optionally comprising the amino acid sequence of SEQ ID NO: 52; and combinations thereof; or
ii) a first polypeptide monomer of the two or more polypeptide monomers comprises a first ligand binding domain, a second polypeptide monomer of the two or more polypeptide monomers comprises a second ligand binding domain, and wherein the second ligand binding domain is different from the first ligand binding domain; and
b) a pharmaceutically acceptable carrier.

### Claim 25

An inducible cell death system comprising an activation-conditional control polypeptide (ACP),
wherein the ACP comprises a ligand binding domain and a transcriptional effector domain, and
wherein upon binding of the ligand binding domain to a cognate ligand, the ACP is capable of modulating transcriptional expression of a gene of interest operably linked to an ACP-responsive promoter,
wherein the gene of interest comprises a cell death inducing polypeptide.

### Claim 26 (depends on 25)

The inducible cell death system comprising an activation-conditional control polypeptide (ACP) of claim 25, wherein the ligand binding domain comprises a degron, optionally wherein the degron is capable of inducing degradation of the ACP,
optionally wherein the degron is selected from the group consisting of HCV NS4 degron, PEST (two copies of residues 277-307 of human IκBα), GRR (residues 352-408 of human p105), DRR (residues 210-295 of yeast Cdc34), SNS (tandem repeat of SP2 and NB (SP2-NB-SP2 of influenza A or influenza B), RPB (four copies of residues 1688-1702 of yeast RPB), SPmix (tandem repeat of SP1 and SP2 (SP2-SP1-SP2-SP1-SP2 of influenza A virus M2 protein), NS2 (three copies of residues 79-93 of influenza A virus NS protein), ODC (residues 106-142 of ornithine decarboxylase), Nek2A, mouse ODC (residues 422-461), mouse ODC_DA (residues 422-461 of mODC including D433A and D434A point mutations), an APC/C degron, a COP1 E3 ligase binding degron motif, a CRL4-Cdt2 binding PIP degron, an actinfilin-binding degron, a KEAP1 binding degron, a KLHL2 and KLHL3 binding degron, an MDM2 binding motif, an N-degron, a hydroxyproline modification in hypoxia signaling, a phytohormone-dependent SCF-LRR-binding degron, an SCF ubiquitin ligase binding phosphodegron, a phytohormone-dependent SCF-LRR-binding degron, a DSGxxS phospho-dependent degron, an Siah binding motif, an SPOP SBC docking motif, and a PCNA binding PIP box, or the degron comprises a cereblon (CRBN) polypeptide substrate domain capable of binding CRBN in response to an immunomodulatory drug (IMiD) thereby promoting ubiquitin pathway-mediated degradation of the regulatable polypeptide, optionally wherein the CRBN polypeptide substrate domain is selected from the group consisting of: IKZF1, IKZF3, CKla, ZFP91, GSPT1, MEIS2, GSS E4F1, ZN276, ZN517, ZN582, ZN653, ZN654, ZN692, ZN787, and ZN827, or a fragment thereof that is capable of drug-inducible binding of CRBN, optionally wherein the CRBN polypeptide substrate domain is a chimeric fusion product of native CRBN polypeptide sequences, optionally wherein the CRBN polypeptide substrate domain is a IKZF3/ZFP91/IKZF3 chimeric fusion product having the amino acid sequence of
(SEQ ID NO: 103)
FNVLMVHKRSHTGERPLQCEICGFTCRQKGNLLRHIKLHTGEKPFKCHLC
NYACQRRDAL.

### Claim 27 (depends on 25)

The inducible cell death system comprising an activation-conditional control polypeptide (ACP) of claim 25, wherein the transcriptional effector domain is comprised in a transcription factor that further comprises a nucleic acid-binding domain.

### Claim 28 (depends on 25)

The inducible cell death system comprising an activation-conditional control polypeptide (ACP) of claim 25, wherein the transcriptional effector domain is selected from the group consisting of: a Herpes Simplex Virus Protein 16 (VP16) activation domain; an activation domain comprising four tandem copies of VP16, a VP64 activation domain; a p65 activation domain of NFκB; an Epstein-Barr virus R transactivator (Rta) activation domain; a tripartite activator comprising the VP64, the p65, and the Rta activation domains (VPR activation domain); a tripartite activator comprising the VP64, the p65, and the HSF1 activation domains (VPH activation domain); a histone acetyltransferase (HAT) core domain of the human E1A-associated protein p300 (p300 HAT core activation domain); a Krüppel associated box (KRAB) repression domain; a Repressor Element Silencing Transcription Factor (REST) repression domain; a WRPW motif of the hairy-related basic helix-loop-helix repressor proteins, the motif is known as a WRPW repression domain; a DNA (cytosine-5)-methyltransferase 3B (DNMT3B) repression domain; and an HP1 alpha chromoshadow repression domain.

### Claim 29 (depends on 25)

The inducible cell death system comprising an activation-conditional control polypeptide (ACP) of claim 25, wherein:
the ligand binding domain comprises: a hormone-binding domain of estrogen receptor (ER) domain optionally comprising the amino acid sequence of SEQ ID NO: 42, optionally wherein the cognate ligand is tamoxifen or a metabolite thereof, and optionally wherein the tamoxifen metabolite is selected from the group consisting of: 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen; or
the ligand binding domain comprises: a progesterone receptor domain optionally comprising the amino acid sequence of SEQ ID NO: 52, and optionally wherein the cognate ligand is mifepristone or a derivative thereof, or
the ligand binding domain comprises: a domain or functional fragment thereof selected from the group consisting of: an ABI domain, optionally comprising the amino acid sequence of SEQ ID NO: 31, and optionally wherein the cognate ligand is abscisic acid; a PYL domain, optionally comprising the amino acid sequence of SEQ ID NO: 53, and optionally wherein the cognate ligand is abscisic acid; a caffeine-binding single-domain antibody optionally comprising the amino acid sequence of SEQ ID NO: 33, and optionally wherein the cognate ligand is caffeine or a derivative thereof; a cannabidiol binding domain, optionally comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 34, 35, 36, 37, and 38, optionally wherein the cognate ligand is a phytocannabinoid, optionally wherein the phytocannabinoid is cannabidiol; a hormone-binding domain of estrogen receptor (ER) domain optionally comprising the amino acid sequence of SEQ ID NO: 42, optionally wherein the cognate ligand is tamoxifen or a metabolite thereof, and optionally wherein the tamoxifen metabolite is selected from the group consisting of: 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen; a heavy chain variable region (VH) of an anti-nicotine antibody optionally comprising the amino acid sequence of SEQ ID NO: 50, and optionally wherein the cognate ligand is nicotine or a derivative thereof; a light chain variable region (VL) of an anti-nicotine antibody optionally comprising the amino acid sequence of SEQ ID NO: 51, and optionally wherein the cognate ligand is nicotine or a derivative thereof; a progesterone receptor domain optionally comprising the amino acid sequence of SEQ ID NO: 52, and optionally wherein the cognate ligand is mifepristone or a derivative thereof; an FRB domain optionally comprising the amino acid sequence of SEQ ID NO: 44, and optionally wherein the cognate ligand is rapamycin, AP1903, AP20187, FK1012, derivatives thereof, or analogs thereof.

### Claim 30 (depends on 25)

The inducible cell death system comprising an activation-conditional control polypeptide (ACP) of claim 25, wherein:
the nucleic acid-binding domain comprises a DNA-binding zinc finger protein domain (ZF protein domain), optionally wherein the ZF protein domain is modular in design and is composed of an array of zinc finger motifs, optionally wherein the ZF-protein domain comprises one to ten zinc finger motifs.

### Claim 31 (depends on 25)

The inducible cell death system comprising an activation-conditional control polypeptide (ACP) of claim 25, wherein: the gene of interest is a cell death-inducing polypeptide, optionally wherein the cell death-inducing domain is derived from a protein selected from the group consisting of: caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, Diphtheria toxin fragment A (DTA), Bax, Bak, Bok, Bad, Bcl-xS, Bak, Bik, Bcl-2-interacting protein 3 (BNIP3), Fas, Fas-associated protein with death domain (FADD), tumor necrosis factor receptor type 1-associated death domain protein (TRADD), a TNF receptor (TNF-R), APAF-1, granzyme B, second mitochondria-derived activator of caspases (SMAC), Omi, Bmf, Bid, Bim, p53-upregulated modulator of apoptosis (PUMA), Noxa, Blk, Hrk, Cytochrome c, Arts, TNF-related cell death-inducing ligand (TRAIL), Herpes Simplex Virus thymidine kinase (HSV-TK), Varicella Zoster Virus thymidine kinase (VZV-TK), viral Spike protein, Carboxyl esterase, cytosine deaminase, nitroreductase Fksb, Carboxypeptidase G2, Carboxypeptidase A, Horseradish peroxidase, Linamarase, Hepatic cytochrome P450-2B1, and Purine nucleoside phosphorylase, optionally wherein the caspase 9 or a functional truncation thereof, comprises the amino acid sequence of SEQ ID NO: 39, optionally wherein the DTA comprises the amino acid sequence of SEQ ID NO: 41, optionally wherein the granzyme B comprises the amino acid sequence of SEQ ID NO: 47, optionally wherein the Bax comprises the amino acid sequence of SEQ ID NO: 32.

### Claim 32 (depends on 25)

A pharmaceutical composition comprising:
a. the inducible cell death system comprising an activation-conditional control polypeptide (ACP) of claim 25; or an isolated cell comprising the inducible cell death system comprising an activation-conditional control polypeptide (ACP) of claim 25; or an engineered nucleic acid encoding the inducible cell death system comprising an activation-conditional control polypeptide (ACP) of claim 25; and
b. a pharmaceutically acceptable carrier.

### Claim 33 (depends on 32)

A method of treating a subject in need thereof, comprising administering to the subject a therapeutically effective dose of a pharmaceutical composition of claim 32.

### Claim 34

A multimeric activation-conditional control polypeptide (ACP) comprising:
a) a first chimeric polypeptide, wherein the first chimeric polypeptide comprises a first ligand binding domain and a transcriptional activation domain; and
b) a second chimeric polypeptide, wherein the second chimeric polypeptide comprises a second ligand binding domain and a nucleic acid-binding domain,
wherein the first chimeric polypeptide and the second chimeric polypeptide oligomerize to form the multimeric ACP via a cognate ligand that binds to each ligand binding domain, and wherein the multimeric ACP is capable of inducing transcriptional expression of a gene of interest operably linked to an ACP-responsive promoter,
wherein the gene of interest is a cell death-inducing polypeptide, optionally wherein the cell death-inducing domain is derived from a protein selected from the group consisting of: caspase 3, caspase 6, caspase 7, caspase 8, caspase 9, Diphtheria toxin fragment A (DTA), Bax, Bak, Bok, Bad, Bcl-xS, Bak, Bik, Bcl-2-interacting protein 3 (BNIP3), Fas, Fas-associated protein with death domain (FADD), tumor necrosis factor receptor type 1-associated death domain protein (TRADD), a TNF receptor (TNF-R), APAF-1, granzyme B, second mitochondria-derived activator of caspases (SMAC), Omi, Bmf, Bid, Bim, p53-upregulated modulator of apoptosis (PUMA), Noxa, Blk, Hrk, Cytochrome c, Arts, TNF-related cell death-inducing ligand (TRAIL), Herpes Simplex Virus thymidine kinase (HSV-TK), Varicella Zoster Virus thymidine kinase (VZV-TK), viral Spike protein, Carboxyl esterase, cytosine deaminase, nitroreductase Fksb, Carboxypeptidase G2, Carboxypeptidase A, Horseradish peroxidase, Linamarase, Hepatic cytochrome P450-2B 1, and Purine nucleoside phosphorylase, optionally wherein the caspase 9 or a functional truncation thereof, comprises the amino acid sequence of SEQ ID NO: 39, optionally wherein the DTA comprises the amino acid sequence of SEQ ID NO: 41, optionally wherein the granzyme B comprises the amino acid sequence of SEQ ID NO: 47, optionally wherein the Bax comprises the amino acid sequence of SEQ ID NO: 32, and wherein the transcriptional activation domain is selected from the group consisting of: a Herpes Simplex Virus Protein 16 (VP16) activation domain; an activation domain comprising four tandem copies of VP16; a VP64 activation domain; a p65 activation domain of NFκB; an Epstein-Barr virus R transactivator (Rta) activation domain; a tripartite activator comprising the VP64, the p65, and the Rta activation domains (VPR activation domain); a tripartite activator comprising the VP64, the p65, and the HSF1 activation domains (VPH activation domain); and a histone acetyltransferase (HAT) core domain of the human E1A-associated protein p300 (p300 HAT core activation domain).

### Claim 35 (depends on 34)

The multimeric activation-conditional control polypeptide (ACP) of claim 34, wherein the one or more ligand binding domains of a first of the two or more polypeptide monomers comprise a cereblon domain, optionally comprising the amino acid sequence set forth in one of SEQ ID NOs: 127 and 129, and the one or more ligand binding domains of a second of the two or more polypeptide monomers comprise a degron, optionally comprising the amino acid sequence set forth in one of SEQ ID NOs: 131 and 133, optionally wherein the cognate ligand is an IMiD, optionally wherein the IMiD is an FDA-approved drug, and optionally wherein the IMiD is selected from the group consisting of: thalidomide, lenalidomide, and pomalidomide.

### Claim 36 (depends on 34)

The multimeric activation-conditional control polypeptide (ACP) of claim 34, wherein the nucleic acid-binding domain comprises a DNA-binding zinc finger protein domain (ZF protein domain), optionally wherein the ZF protein domain is modular in design and is composed of an array of zinc finger motifs, optionally wherein the ZF-protein domain comprises one to ten zinc finger motifs.

### Claim 37 (depends on 34)

The multimeric activation-conditional control polypeptide (ACP) of claim 34, wherein the nucleic acid-binding domain binds to the ACP-responsive promoter, optionally wherein the ACP-responsive promoter comprises an ACP-binding domain sequence and a promoter sequence, optionally wherein the promoter sequence comprises a minimal promoter, optionally wherein the promoter sequence is an inducible promoter and further comprises a responsive element selected from the group consisting of: NFκB response element, CREB response element, NFAT response element, SRF response element 1, SRF response element 2, AP1 response element, TCF-LEF response element promoter fusion, Hypoxia responsive element, SMAD binding element, STAT3 binding site, inducer molecule-responsive promoters, and tandem repeats thereof, and optionally wherein the ACP-responsive promoter comprises a synthetic promoter, and optionally wherein the ACP-binding domain comprises one or more zinc finger binding sites.

### Claim 38 (depends on 34)

The multimeric activation-conditional control polypeptide (ACP) of claim 34, wherein the one or more ligand binding domains of each of the two or more polypeptide monomers comprise a domain or functional fragment thereof selected from the group consisting of: an ABI domain, optionally comprising the amino acid sequence of SEQ ID NO: 31, and optionally wherein the cognate ligand is abscisic acid; a PYL domain, optionally comprising the amino acid sequence of SEQ ID NO: 53, and optionally wherein the cognate ligand is abscisic acid; a caffeine-binding single-domain antibody optionally comprising the amino acid sequence of SEQ ID NO: 33, and optionally wherein the cognate ligand is caffeine or a derivative thereof; a cannabidiol binding domain, optionally comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 34, 35, 36, 37, and 38, optionally wherein the cognate ligand is a phytocannabinoid, optionally wherein the phytocannabinoid is cannabidiol; a hormone-binding domain of estrogen receptor (ER) domain optionally comprising the amino acid sequence of SEQ ID NO: 42, optionally wherein the cognate ligand is tamoxifen or a metabolite thereof, and optionally wherein the tamoxifen metabolite is selected from the group consisting of: 4-hydroxytamoxifen, N-desmethyltamoxifen, tamoxifen-N-oxide, and endoxifen; a heavy chain variable region (VH) of an anti-nicotine antibody optionally comprising the amino acid sequence of SEQ ID NO: 50, and optionally wherein the cognate ligand is nicotine or a derivative thereof; a light chain variable region (VL) of an anti-nicotine antibody optionally comprising the amino acid sequence of SEQ ID NO: 51, and optionally wherein the cognate ligand is nicotine or a derivative thereof; a progesterone receptor domain optionally comprising the amino acid sequence of SEQ ID NO: 52, and optionally wherein the cognate ligand is mifepristone or a derivative thereof; an FRB domain optionally comprising the amino acid sequence of SEQ ID NO: 44, and optionally wherein the cognate ligand is rapamycin, AP1903, AP20187, FK1012, derivatives thereof, or analogs thereof; or
the one or more ligand binding domains of a first of the two or more polypeptide monomers comprise an FKBP domain, optionally comprising the amino acid sequence of SEQ ID NO: 43, and the one or more ligand binding domains of a second of the two or more polypeptide monomers comprise an FRB domain, optionally comprising the amino acid sequence of SEQ ID NO: 44, optionally wherein the cognate ligand is rapamycin, AP1903, AP20187, FK1012, derivatives thereof, or analogs thereof.

### Claim 39 (depends on 34)

A pharmaceutical composition comprising:
a. the multimeric activation-conditional control polypeptide (ACP) of claim 34; or an isolated cell comprising the multimeric activation-conditional control polypeptide (ACP) of claim 34; or an engineered nucleic acid encoding the multimeric activation-conditional control polypeptide (ACP) of claim 34; and
b. a pharmaceutically acceptable carrier.

### Claim 40 (depends on 39)

A method of treating a subject in need thereof, comprising administering to the subject a therapeutically effective dose of a pharmaceutical composition of claim 39.
